-
平臺編號：bio-68300
-
國際編號：HB-11534?
-
細胞信息： DC101
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
DC101
運輸方式：凍存運輸
細胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
數(shù)量：大量
ATCC Number：HB-11534?
生長狀態(tài)：懸浮生長
是否是腫瘤細胞：0
物種來源：大鼠
規(guī)格：0.2ml Designations: DC101
Depositors: ?ImClone Systems Inc.
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma:
Cellular Products:immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.
Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization
Comments:DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.
DC101 does not cross-react with the human VEGFR2/KDR.
Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization
Animals were hyperimmunized with an immune complex consisting of the mouse FLK-1:SEAPs soluble receptor, a rabbit anti-alkaline phosphatase polyclonal antibody and Protein-G sepharose beads.
Spleen cells were fused with NS-1 mouse myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 92.5%; DMSO, 7.5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 47436: Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 5,955,311 dated Sep 21 1999
55760: Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17: 155-161, 1998. PubMed: 9770111
56114: Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209-5218, 1999. PubMed: 10537299
56115: Shaheen RM, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 18: 221-226, 2001. PubMed: 11172585
56116: Kadambi A, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61: 2404-2408, 2001. PubMed: 11289105
56117: Kozin SV, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44, 2001. PubMed: 11196192
56142: Zimmermann RC, et al. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc. Res. 62: 15-25, 2001. PubMed: 11421657
56143: Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24, 2000. PubMed: 10772661
56145: Stoelcker B, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J. Inferon Cytokine Res. 20: 511-517, 2000. PubMed: 10841080
細胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
數(shù)量：大量
ATCC Number：HB-11534?
生長狀態(tài)：懸浮生長
是否是腫瘤細胞：0
物種來源：大鼠
規(guī)格：0.2ml Designations: DC101
Depositors: ?ImClone Systems Inc.
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma:
Cellular Products:immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.
Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization
Comments:DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.
DC101 does not cross-react with the human VEGFR2/KDR.
Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization
Animals were hyperimmunized with an immune complex consisting of the mouse FLK-1:SEAPs soluble receptor, a rabbit anti-alkaline phosphatase polyclonal antibody and Protein-G sepharose beads.
Spleen cells were fused with NS-1 mouse myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 92.5%; DMSO, 7.5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 47436: Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 5,955,311 dated Sep 21 1999
55760: Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17: 155-161, 1998. PubMed: 9770111
56114: Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209-5218, 1999. PubMed: 10537299
56115: Shaheen RM, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 18: 221-226, 2001. PubMed: 11172585
56116: Kadambi A, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61: 2404-2408, 2001. PubMed: 11289105
56117: Kozin SV, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44, 2001. PubMed: 11196192
56142: Zimmermann RC, et al. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc. Res. 62: 15-25, 2001. PubMed: 11421657
56143: Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24, 2000. PubMed: 10772661
56145: Stoelcker B, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J. Inferon Cytokine Res. 20: 511-517, 2000. PubMed: 10841080
